IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LIGORIO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.655
NA - Nord America 1.617
AS - Asia 1.481
Continente sconosciuto - Info sul continente non disponibili 125
SA - Sud America 116
AF - Africa 44
OC - Oceania 7
Totale 5.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.540
DE - Germania 671
IT - Italia 491
CN - Cina 416
SG - Singapore 404
BD - Bangladesh 161
HK - Hong Kong 160
BR - Brasile 87
IN - India 85
VN - Vietnam 83
NL - Olanda 82
FR - Francia 76
RU - Federazione Russa 68
GB - Regno Unito 65
SE - Svezia 61
CA - Canada 50
FI - Finlandia 45
JP - Giappone 34
TR - Turchia 25
KR - Corea 24
CI - Costa d'Avorio 22
IE - Irlanda 22
ID - Indonesia 17
PL - Polonia 14
DK - Danimarca 11
PH - Filippine 11
ES - Italia 9
MX - Messico 9
RO - Romania 9
TW - Taiwan 9
NP - Nepal 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
AR - Argentina 7
CO - Colombia 7
SA - Arabia Saudita 7
BE - Belgio 6
AT - Austria 5
IQ - Iraq 5
AU - Australia 4
CL - Cile 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JM - Giamaica 4
TT - Trinidad e Tobago 4
CR - Costa Rica 3
EC - Ecuador 3
HU - Ungheria 3
MY - Malesia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
BB - Barbados 2
CH - Svizzera 2
GT - Guatemala 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
TN - Tunisia 2
VE - Venezuela 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MV - Maldive 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
SV - El Salvador 1
TH - Thailandia 1
TM - Turkmenistan 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 4.922
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 619
Ashburn 259
Singapore 199
San Jose 145
Hong Kong 133
Milan 128
Dallas 117
Council Bluffs 84
Hefei 83
Santa Clara 83
Los Angeles 66
Beijing 62
Chandler 45
New York 38
Boardman 30
Helsinki 30
Rome 30
Bengaluru 29
Fairfield 29
Ho Chi Minh City 25
Abidjan 22
Dublin 22
Lauterbourg 21
Moscow 21
Southend 21
Hanoi 19
Naples 18
Tokyo 18
Buffalo 17
Guangzhou 17
Houston 16
Hyderabad 16
Cambridge 15
Montreal 15
Jakarta 14
Orem 14
Wilmington 13
London 12
Nuremberg 12
Amsterdam 11
Atlanta 11
Cangzhou 11
Denver 11
Düsseldorf 11
Istanbul 11
Munich 11
Seattle 11
Shenzhen 11
Phoenix 10
Shanghai 10
Stockholm 10
Bucharest 9
Chicago 9
Dong-gu 9
Genoa 9
Lappeenranta 9
Salt Lake City 9
San Francisco 9
Seoul 9
São Paulo 9
Fuzhou 8
Hangzhou 8
Manchester 8
Princeton 8
Bologna 7
Florence 7
Redwood City 7
Shenyang 7
Tashkent 7
Woodbridge 7
Chennai 6
Miami 6
Padua 6
Paris 6
Philadelphia 6
Berlin 5
Boston 5
Elk Grove Village 5
Iwasakichō 5
Jacksonville 5
Mumbai 5
New Delhi 5
Pessac 5
Taipei 5
Toronto 5
Turku 5
Warsaw 5
Bari 4
Bochum 4
Brussels 4
Cairo 4
Charlotte 4
Dearborn 4
Dhaka 4
Johannesburg 4
Juiz de Fora 4
McAllen 4
Medellín 4
Nanjing 4
Orlando 4
Totale 2.983
Salva come PNG Salva come JPEG
Nome #
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 550
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer 440
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab 344
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence 268
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 237
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 235
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 227
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin 204
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 199
Wave climate at shallow waters along the Abu Dhabi coast 196
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 192
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 187
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 185
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 183
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 180
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 165
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer 131
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis 127
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis 126
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications 113
HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness 111
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications 111
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 91
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer 83
Fasting-mimicking diet plus chemotherapy in breast cancer treatment 78
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study 29
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 27
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib 22
null 3
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 5.045
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.146
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022177 0 25 15 18 13 13 7 18 25 14 9 20
2022/2023214 17 24 14 10 26 47 9 19 23 1 21 3
2023/2024630 22 16 11 16 54 32 101 80 36 77 96 89
2024/20251.132 72 93 86 84 47 43 77 116 80 116 101 217
2025/20262.351 233 200 228 161 133 95 250 88 272 218 256 217
2026/2027393 256 137 0 0 0 0 0 0 0 0 0 0
Totale 5.045